Every material Form 8-K Bio-Techne filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bio-Techne's Compensation Committee granted Chief Financial Officer James Hippel a one-time restricted stock unit award of 34,634 shares on October 30, 2024. The company said the award is for retention and follows forfeited stock options that were lost because of a stock plan administrative error.
Award of 34,634 restricted stock units granted October 30, 2024 under the 2020 Equity Incentive Plan
Units vest in equal installments on the first three anniversaries of the grant date, subject to continued service
Company cites retention and forfeited stock options lost due to an administrative error in recording the expiration date
Bio-Techne reported first-quarter fiscal 2025 results for the quarter ended September 30, 2024, with net sales up 5% to $289.5 million and adjusted EPS of $0.42, versus $0.41 a year earlier. GAAP EPS fell to $0.21 from $0.31, and GAAP operating income dropped 28% to $40.0 million, which the company attributes partly to restructuring charges. The company also declared a quarterly dividend of $0.08 per share and reported shareholder votes from its annual meeting.
Net sales rose 5% to $289.5 million; organic growth was 4%.
GAAP EPS was $0.21 versus $0.31 a year earlier; adjusted EPS was $0.42 versus $0.41.
GAAP operating margin was 13.8%, compared with 20.2%; adjusted operating margin was 29.0%, compared with 31.4%.
Quarterly dividend of $0.08 per share is payable November 22, 2024, to shareholders of record on November 11, 2024.
Bio-Techne reported fourth-quarter fiscal 2024 net sales up 2% to $306.1 million, with organic revenue up 1%, while GAAP earnings per share fell to $0.25 from $0.47 a year earlier. Full-year net sales rose 2% to $1.2 billion, but full-year GAAP EPS fell to $1.05 from $1.76, and the company also announced a cash dividend in a separate press release.
Q4 GAAP operating income fell 52% to $45.8 million; adjusted operating income fell 9% to $101.8 million
Q4 adjusted EPS was $0.49 versus $0.55 a year earlier; full-year adjusted EPS was $1.77 versus $1.99
Diagnostics and Genomics segment Q4 net sales rose 15% to $90.7 million, while Protein Sciences Q4 net sales fell 4% to $214.0 million
Full-year cash flow from operations rose 18% to $299.0 million; the filing does not state the dividend amount
Bio-Techne reported third-quarter fiscal 2024 results for the period ended March 31, 2024, with net sales up 3% to $303.4 million. Profit declined: GAAP EPS fell to $0.31 from $0.43 and adjusted EPS fell to $0.48 from $0.53, and the company attributed the margin pressure to restructuring and CEO transition costs, the Lunaphore acquisition, and unfavorable volume leverage within Protein Sciences. The Board also declared a $0.08 per share quarterly dividend.
Net sales rose 3% to $303.4 million; organic revenue rose 2%
GAAP EPS was $0.31 versus $0.43 a year earlier; adjusted EPS was $0.48 versus $0.53
GAAP operating income fell 16% to $67.0 million; adjusted operating margin was 33.0% versus 37.0%
Dividend of $0.08 per share payable May 24, 2024, to holders of record on May 13, 2024
Bio-Techne expanded its board from ten to eleven members on April 24, 2024, and appointed Dr. Judith Klimovsky, currently Executive Vice President and Chief Development Officer at Genmab, as an independent director. The filing also discloses a one-year waiver of the board's mandatory retirement policy for Dr. Roeland Nusse. The change is a board governance update with no financial figures reported.
Dr. Judith Klimovsky appointed as independent director effective April 24, 2024, to the Science and Technology Committee
Board temporarily expanded from ten to eleven members, ten of whom are independent
Board approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bio-Techne filing is on SEC EDGAR ↗. 8-K briefs of other companies →